Australia's Bioxyne surges after raising fiscal year revenue outlook

BLS Pharmaceuticals

12/06/2025 02:28

** Shares of Bioxyne BXN.AX surge as much as 30.8% to A$0.034, their highest level since March 21

** Stock marks biggest intraday pct gain since Oct 17, 2024

** Pharmaceutical firm upgrades FY25 revenue forecast to A$28 mln ($18.21 mln) from A$25 mln

** H2 revenue to be A$15.4 mln, up 226% pcp

** Trading volume at around 19.2 mln shares vs 30-day average of 2.2 mln

** Stock up 11.1% YTD

($1 = 1.5373 Australian dollars)

 (Reporting by Sneha Kumar in Bengaluru)

 ((Sneha.kumar@thomsonreuters.com;))